
For the first time, a person has been dosed with Lu AG22515, a candidate that Lundbeck acquired for USD 16m upfront payment from South Korean biotech company Aprilbio in October last year, in a deal which also included potential milestone payments of USD 432m.
Lundbeck revealed this in its first quarterly report for 2021 last week, noting that the study began back in March.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app